Lea Chen is a Gastroenterology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Robert Wood Johnson Pl
New Brunswick, NJ 089011928
Telephone
732-828-3000Provider last certified this registry record 23 Jul 2021.
Clinical trials
- Managing Infliximab Reinduction After Temporary Discontinuation of Drug
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20255 payments
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20251 payment
- Janssen Biotech, Inc.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.1%Integrin Receptor Antagonist52.1%Entyvio100%Part D<11 patientsRespiratory
47.9%Corticosteroid47.9%Budesonide Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Gut microbiome manipulation to improve efficacy and durability of anti-TNF treatments for inflammatory bowel disease
Rutgers Biomedical and Health Sciences
FY2026$772,697R01DK142698 - Gut Microbial Functions that Impact Multiplex and Non-multiplex Crohn’s Disease Risk.
Rutgers Biomedical and Health Sciences
FY2025$235,500R03DK142053 - The Study of Families with Heritable Crohn's Disease to Support Rational Design of Microbiodata-Based Therapies
Rutgers Biomedical and Health Sciences
FY2024$217,323K23DK119544
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”